Business Context and Reporting Period
This Form 8-K filing by Qualigen Therapeutics, Inc. (QLGN) covers events occurring between September 26, 2025, and October 3, 2025. The report details significant corporate governance changes, including the resignation of the independent registered public accounting firm, the appointment of a new auditor, and major restructuring of the executive leadership and Board of Directors.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, or debt figures. However, it notes that the former auditor's reports for the fiscal year ended December 31, 2024, included an explanatory paragraph regarding substantial doubt about the Company's ability to continue as a going concern. The filing also identifies material weaknesses in internal controls over financial reporting related to insufficient accounting personnel, lack of effective IT general controls, and lack of formalized process documentation.
Material Changes Versus Prior Period
- Accounting Firm Change: WithumSmith+Brown, PC resigned effective October 1, 2025. Macias Gini & O'Connell LLP (MGO) was appointed as the new independent auditor effective October 3, 2025.
- Executive Leadership: Jiawei Wang was appointed Co-Chief Executive Officer and Koti Meka was appointed Chief Financial Officer, both effective October 2, 2025.
- Board Composition: Three new directors (Kevin Chen, Chad Chen, and Jie Sheng) were appointed. Three directors (Cody Price, Robert Lim, and Campbell Becher) resigned from the Board, though Mr. Becher remains as President.
- Committee Restructuring: New committee appointments were made, with Jie Sheng named Chairman of the Audit Committee.
Guidance, Outlook, and Risks
The filing does not contain forward-looking financial guidance or management commentary on future performance. Key risks and contingencies highlighted include:
- Going Concern: The prior auditor's report contained a substantial doubt opinion regarding the Company's ability to continue as a going concern.
- Internal Controls: Material weaknesses exist in internal controls over financial reporting, specifically regarding segregation of duties, IT access controls, and documentation of processes.
- Transition Risk: The Company is in the process of transitioning to a new audit firm and new executive leadership, which may impact operational continuity.
Investor Verification Checklist
- Verify the reasons for WithumSmith+Brown's resignation and review the accompanying letter (Exhibit 16.1) for any undisclosed disagreements.
- Confirm the status of the Company's liquidity and capital resources given the "substantial doubt" going concern warning.
- Review the Company's plan to remediate the identified material weaknesses in internal controls over financial reporting.
- Assess the impact of the new executive team and Board composition on the Company's strategic direction.
- Monitor the progress of the new auditor, MGO, in completing client acceptance procedures and commencing interim reviews.